Inventiva S.A. (IVA)
| Previous Close | 6.15 |
| Open | 6.13 |
| Bid | 5.51 x 1000 |
| Ask | 6.30 x 900 |
| Day's Range | 6.05 - 6.30 |
| 52 Week Range | 3.49 - 13.66 |
| Volume | |
| Avg. Volume | 8,533 |
| Market Cap | 266.442M |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.33 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023
Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ General Meeting. The Combined Shareholders' Meeting was held on January 25, 2023 at 2 p.m. at Hôtel Oc
- GlobeNewswire
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population to patients with NASH and compensated cirrhosis Confirmatory trial of lanifibranor clinical benefits, which was initially planned to be evaluated in Part 2 of NATiV3 trial in patients with NASH and F2/F3 fibrosis, is now planned t
- GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022
Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2) December 19, 2022 42 134 169 55 144 801 55 029 868 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calcula
